

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

18/LG/SE/JAN/2025/GBSL

January 31, 2025

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001
Scrip Code: 509079

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Scrip Symbol: GUFICBIO

Sub.: Intimation of grant of Patent in Europe

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we are pleased to inform that the Company has been granted patent in Europe for an invention titled "**A FREEZE DRIED PARENTERAL COMPOSITION OF OMADACYCLINE TOSYLATE WITH IMPROVED STABILITY**" on January 29, 2025 for the term of 20 years effective from June 5, 2023. The intimation in this regard was received by the Company on January 31, 2025.

Omadacycline Tosylate is approved in the United States for the treatment of **Community-Acquired Bacterial Pneumonia (CABP)** and **Acute Bacterial Skin and Skin Structure Infections (ABSSSI)**.

Kindly take the same on record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited

Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579